Detection of circulating tumor cells in sufferers with breast most cancers utilizing the conditionally reprogrammed cell tradition methodology and reverse transcription-PCR of hTERT and MAGE A1-6
The current research aimed to confirm the efficacy of the conditionally reprogrammed cell (CRC) tradition methodology for the detection of circulating tumor cells (CTCs) in breast most cancers. CTCs have been remoted from the peripheral blood of sufferers with breast most cancers, and tradition of the collected CTCs was carried out in response to the conditional reprogramming protocol.
- Whole RNA was extracted from cultured CTCs, and the hTERT and MAGE A1-6 genes have been amplified utilizing reverse transcription-PCR (RT-PCR). As well as, RNA extraction from one other blood pattern was carried out and the expression of the 2 genes was analyzed by RT-PCR solely.
- Following CRC tradition, grown CTCs have been noticed in 7 samples (23.3%). The CTC detection charges by RT-PCR for the hTERT and MAGE A1-6 genes in CTCs grown utilizing the CRC tradition methodology have been 26.7 and 10.0%, respectively.
- The optimistic expression charges for the hTERT and MAGE genes in CTCs assessed by RT-PCR solely have been 44.1 and 23.5%, respectively. When combining the optimistic expression charges of RT-PCR solely and CRC tradition for the hTERT and MAGE A1-6 genes, CTC detection charges elevated to 53.Three and 23.3%, respectively. Moreover, when combining the optimistic expression charges of the 2 genes by both methodology, the CTC detection price was the best worth noticed.
- In conclusion, the current research revealed the potential of CRC tradition within the detection of CTCs in breast most cancers. Moreover, a mixture of CRC tradition and RT-PCR for the hTERT and MAGE A1-6 genes is helpful in enhancing the detection price of CTCs within the blood.
 GPR81 antibody |
|||
| 20R-GR037 | Fitzgerald | 50 ug | EUR 679.00 |
|
Description: Rabbit polyclonal GPR81 antibody |
|||
|
GPR81 antibody |
|||
| 20R-GR038 | Fitzgerald | 50 ug | EUR 679.00 |
|
Description: Rabbit polyclonal GPR81 antibody |
|||
 GPR81 Antibody |
|||
| 44942-100ul | SAB | 100ul | EUR 252.00 |
|
GPR81 Antibody |
|||
| 44942-50ul | SAB | 50ul | EUR 187.00 |
|
GPR81 Antibody |
|||
| DF2766 | Affbiotech | 200ul | EUR 304.00 |
|
Description: GPR81 antibody detects endogenous levels of total GPR81. |
|||
|
GPR81 antibody |
|||
| 70R-50946 | Fitzgerald | 100 ul | EUR 244.00 |
|
Description: Purified Polyclonal GPR81 antibody |
|||
|
GPR81 Antibody |
|||
| ABD2766 | Lifescience Market | 100 ug | EUR 438.00 |
 Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 349.00 |
 Polyclonal Goat Anti-GPR81 / FKSG80 Antibody |
|||
| APR16285G | Leading Biology | 0.1 mg | EUR 484.00 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-GPR81 / FKSG80 . This antibody is tested and proven to work in the following applications: |
|||
 GPR81 Conjugated Antibody |
|||
| C44942 | SAB | 100ul | EUR 397.00 |
 GPR81 Blocking Peptide |
|||
| DF2766-BP | Affbiotech | 1mg | EUR 195.00 |
|
GPR81 Blocking Peptide |
|||
| 20-abx063821 | Abbexa |
|
|
|
|||
 pDNR-Dual-GPR81 |
|||
| PVT17473 | Lifescience Market | 2 ug | EUR 231.00 |
) Polyclonal GPR81 Antibody (C-term) |
|||
| APR16611G | Leading Biology | 0.1ml | EUR 484.00 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPR81 (C-term). This antibody is tested and proven to work in the following applications: |
|||
 Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280.00 |
 Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280.00 |
 Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280.00 |
 GPR81 ELISA KIT|Human |
|||
| EF009971 | Lifescience Market | 96 Tests | EUR 689.00 |
) Polyclonal FKSG80 / GPR81 Antibody (C-Terminus) |
|||
| APR15995G | Leading Biology | 0.05mg | EUR 484.00 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (C-Terminus). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal FKSG80 / GPR81 Antibody (Extracellular Domain) |
|||
| APR15996G | Leading Biology | 0.05mg | EUR 484.00 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (Extracellular Domain). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal FKSG80 / GPR81 Antibody (N-Terminus) |
|||
| APR15997G | Leading Biology | 0.05mg | EUR 484.00 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FKSG80 / GPR81 (N-Terminus). This antibody is tested and proven to work in the following applications: |
|||
 (pORF)) Gpr81 ORF Vector (Rat) (pORF) |
|||
| ORF067824 | ABM | 1.0 ug DNA | EUR 506.00 |
 (pORF)) Gpr81 ORF Vector (Mouse) (pORF) |
|||
| ORF046573 | ABM | 1.0 ug DNA | EUR 506.00 |
 Antibody) G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| 20-abx008192 | Abbexa |
|
|
|
|||
|
G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| 20-abx147554 | Abbexa |
|
|
|
|||
|
G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| abx028676-400ul | Abbexa | 400 ul | EUR 523.00 |
|
|||
|
G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| abx028676-80l | Abbexa | 80 µl | EUR 286.00 |
|
|||
|
G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| abx233610-100ug | Abbexa | 100 ug | EUR 551.00 |
|
|||
|
G Protein-Coupled Receptor 81 (GPR81) Antibody |
|||
| abx430538-200ul | Abbexa | 200 ul | EUR 384.00 |
|
|||
) Gpr81 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6130201 | ABM | 3 x 1.0 ug | EUR 339.00 |
) Gpr81 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3904701 | ABM | 3 x 1.0 ug | EUR 339.00 |
) GPR81 sgRNA CRISPR Lentivector set (Human) |
|||
| K0893201 | ABM | 3 x 1.0 ug | EUR 339.00 |
 (Target 1)) Gpr81 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6130202 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 2)) Gpr81 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6130203 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 3)) Gpr81 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6130204 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 1)) Gpr81 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3904702 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 2)) Gpr81 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3904703 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 3)) Gpr81 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3904704 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 1)) GPR81 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0893202 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 2)) GPR81 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0893203 | ABM | 1.0 ug DNA | EUR 154.00 |
 (Target 3)) GPR81 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0893204 | ABM | 1.0 ug DNA | EUR 154.00 |
 (pPB-C-His)) GPR81 Protein Vector (Rat) (pPB-C-His) |
|||
| PV271294 | ABM | 500 ng | EUR 603.00 |
 (pPB-N-His)) GPR81 Protein Vector (Rat) (pPB-N-His) |
|||
| PV271295 | ABM | 500 ng | EUR 603.00 |
 (pPM-C-HA)) GPR81 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV271296 | ABM | 500 ng | EUR 603.00 |
 (pPM-C-His)) GPR81 Protein Vector (Rat) (pPM-C-His) |
|||
| PV271297 | ABM | 500 ng | EUR 603.00 |
 (pPB-C-His)) GPR81 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV186290 | ABM | 500 ng | EUR 603.00 |
 (pPB-N-His)) GPR81 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV186291 | ABM | 500 ng | EUR 603.00 |
 (pPM-C-HA)) GPR81 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV186292 | ABM | 500 ng | EUR 603.00 |
 (pPM-C-His)) GPR81 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV186293 | ABM | 500 ng | EUR 603.00 |
 Gpr81 3'UTR Luciferase Stable Cell Line |
|||
| TU109042 | ABM | 1.0 ml | Ask for price |
|
Gpr81 3'UTR Luciferase Stable Cell Line |
|||
| TU205392 | ABM | 1.0 ml | Ask for price |
 Gpr81 3'UTR GFP Stable Cell Line |
|||
| TU159042 | ABM | 1.0 ml | Ask for price |
|
Gpr81 3'UTR GFP Stable Cell Line |
|||
| TU255392 | ABM | 1.0 ml | Ask for price |
 GPR81 3'UTR GFP Stable Cell Line |
|||
| TU059183 | ABM | 1.0 ml | EUR 1521.00 |
 GPR81 3'UTR Luciferase Stable Cell Line |
|||
| TU009183 | ABM | 1.0 ml | EUR 1521.00 |
) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6130205 | ABM | 3 x 1.0 ug | EUR 376.00 |
) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3904705 | ABM | 3 x 1.0 ug | EUR 376.00 |
) GPR81 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0893205 | ABM | 3 x 1.0 ug | EUR 376.00 |
 (Target 1)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6130206 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 2)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6130207 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 3)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6130208 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 1)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3904706 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 2)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3904707 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 3)) Gpr81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3904708 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 1)) GPR81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0893206 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 2)) GPR81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0893207 | ABM | 1.0 ug DNA | EUR 167.00 |
 (Target 3)) GPR81 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0893208 | ABM | 1.0 ug DNA | EUR 167.00 |
 Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
 Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
 Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
 Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
 Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
|
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
 Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
 Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
|
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
 Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
 Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 277.00 |
 Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 277.00 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
 Anti-Anti-DDB1 Antibody |
|||
| A00333 | BosterBio | 100uL | EUR 455.00 |
|
Description: Rabbit Polyclonal DDB1 Antibody. Validated in IP and tested in Human, Mouse. |
|||
 ELISA Kit) Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-10x96wellstestplate | Cloud-Clone | 10x96-wells test plate | EUR 5647.80 |
|
|||
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
|
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-1x48wellstestplate | Cloud-Clone | 1x48-wells test plate | EUR 552.76 |
|
|||
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
|
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-1x96wellstestplate | Cloud-Clone | 1x96-wells test plate | EUR 746.80 |
|
|||
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
|
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| AEA465Hu-5x96wellstestplate | Cloud-Clone | 5x96-wells test plate | EUR 3060.60 |
|
|||
|
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids. |
|||
|
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit |
|||
| 4-AEA465Hu | Cloud-Clone |
|
|
|
|||
|
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species. |
|||
) ELISA kit for Human Anti-AsAb (Anti-Anti-Sperm Antibody Antibody) |
|||
| ELK8071 | ELK Biotech | 1 plate of 96 wells | EUR 432.00 |
|
|||
|
Description: A competitive Inhibition ELISA kit for detection of Anti-Anti-Sperm Antibody Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
|||
 Anti-CYFIP2 Antibody |
|||
| A06562 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal Antibody for CYFIP2 Antibody (CYFIP2) detection.tested for IHC, WB in Human, Mouse, Rat. |
|||
 Anti-GPS2 Antibody |
|||
| A06569 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal Antibody for GPS2 Antibody (GPS2) detection. Tested with WB in Human, Mouse, Rat. |
|||
 Anti-PRKX Antibody |
|||
| A06585-1 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal PRKX Antibody. Validated in IHC, WB and tested in Human, Mouse, Rat. |
|||
 Anti-PPA2 Antibody |
|||
| A06587 | BosterBio | 100ug/vial | EUR 294.00 |
 Anti-GluR8 Antibody |
|||
| A06589 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal GluR8 Antibody. Validated in IHC, WB and tested in Human, Mouse, Rat. |
|||
 Anti-EDG7 Antibody |
|||
| A06597-1 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal EDG7 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat. |
|||
 Anti-KIR2.3 Antibody |
|||
| A06605-1 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal Antibody for KIR2.3 Antibody (KCNJ4) detection. Tested with WB in Human, Mouse, Rat. |
|||
 Anti-GALK1 Antibody |
|||
| A06627 | BosterBio | 100ul | EUR 397.00 |
|
Description: Rabbit Polyclonal GALK1 Antibody. Validated in WB and tested in Human, Mouse, Rat. |
|||
 Anti-PRAME Antibody |
|||
| A06628-2 | BosterBio | 100ug/vial | EUR 294.00 |
 Anti-GP2 Antibody |
|||
| A06630-1 | BosterBio | 100ug/vial | EUR 334.00 |
Incidence, scientific course and threat issue for recurrent PCR positivity in discharged COVID-19 sufferers in Guangzhou, China: A potential cohort research
The phenomenon of COVID-19 sufferers examined optimistic for SARS-CoV-2 after discharge (redetectable as optimistic, RP) emerged globally. The information of incidence price and threat elements for RP occasion and the scientific options of RP sufferers might present suggestions for virus containment and circumstances administration for COVID-19.
We prospectively collected and analyzed the epidemiological, scientific and virological information from 285 grownup sufferers with COVID-19 and bought their particular scientific final result (getting PCR optimistic or not throughout post-discharge surveillance). By March 10, 27 (9.5%) discharged sufferers had examined optimistic for SARS-CoV-2 of their nasopharyngeal swab after a median length of seven·Zero days (IQR 5·0-8·0).
In comparison with first admission, RP sufferers typically had milder scientific signs, decrease viral load, shorter size of keep and improved pulmonary circumstances at readmission (p<0.05). Elder RP sufferers (≥ 60 years previous) have been extra prone to be symptomatic in comparison with youthful sufferers (7/8, 87.5% vs. 3/19, 18.8%, p = 0.001) at readmission.
Age, intercourse, epidemiological historical past, scientific signs and underlying illnesses have been related between RP and non-RP sufferers (p>0.05). A protracted length of viral shedding (>10 days) throughout the first hospitalization [adjusted odds ratio [aOR]: 5.82, 95% confidence interval [CI]: 2.50-13.57 for N gene; aOR: 9.64, 95% CI: 3.91-23.73 for ORF gene] and better Ct worth (ORF) within the third week of the primary hospitalization (aOR: 0.69; 95% CI: 0.50-0.95) have been related to RP occasions.
In conclusion, RP occasions occurred in practically 10% of COVID-19 sufferers shortly after the detrimental checks, weren’t related to worsening signs and unlikely mirror reinfection. Sufferers’ lack of effectivity in virus clearance was a threat issue for RP end result. It’s noteworthy that elder RP sufferers (≥ 60 years previous) have been extra vulnerable to scientific signs at readmission.
Ovine Paratuberculosis: Seroprevalence and comparability of fecal tradition and direct fecal PCR assay
Johne’s illness is persistent, incurable illness, brought on by Mycobacterium avium subsp. paratuberculosis (MAP). Most research in Egypt targeted on incidence of the illness in cattle however few research have been reported presence of antibodies towards MAP in sheep. The current research decided the seroprevalence price of MAP amongst sheep in 4 Governorates and assessed the related threat elements to MAP-infection.
- The seroprevalence price of MAP amongst sheep was non-significant various between totally different Governorates, it was ranged between 3.75%-12.3%. The outcomes revealed that the seroprevalence price of the illness was considerably elevated in diarrheic sheep (11 %, 95 %CI: 7.2-16.2) throughout spring (15 %, 95 %CI: 8.3-25) and summer time (8%, 95 %CI: 4.13-13.8) seasons.
- Opposite, the age of sheep and make contact with with different ruminants like cattle or goats had non-significant impact of spreading of MAP-infection amongst sheep. The detection of MAP in feces of sheep was carried out utilizing tradition and PCR to find out the effectivity of each checks.
- The kappa check revealed good settlement between each checks for detection of MAP. The obtained discovering confirms the presence of MAP amongst sheep in Egypt. So, the suitable management measures ought to be taken to scale back spreading of the illness amongst sheep and cut back its financial losses.
 RAIDD Blocking Peptide |
|||
| 3037BP-50 | Biovision | EUR 153.00 | |
 NFkB Blocking Peptide |
|||
| 3038BP-50 | Biovision | EUR 153.00 | |
 FADD Blocking Peptide |
|||
| 3039BP-50 | Biovision | EUR 153.00 | |
 PBR Blocking Peptide |
|||
| 3044BP-50 | Biovision | EUR 153.00 | |
 MBD4 Blocking Peptide |
|||
| 3056BP-50 | Biovision | EUR 153.00 | |
 PRMT7 blocking peptide |
|||
| 3059BP-50 | Biovision | EUR 153.00 | |
 DR4 Blocking Peptide |
|||
| 3061BP-50 | Biovision | EUR 153.00 | |
 DR5 Blocking Peptide |
|||
| 3062BP-50 | Biovision | EUR 153.00 | |
 CD40 Blocking Peptide |
|||
| 3072BP-50 | Biovision | EUR 153.00 | |
 Calreticulin Blocking Peptide |
|||
| 3077BP-50 | Biovision | EUR 153.00 | |
 PRMT6 Blocking Peptide |
|||
| 3086BP-50 | Biovision | EUR 153.00 | |
 TCTN1 Blocking Peptide |
|||
| 3087BP-50 | Biovision | EUR 153.00 | |
TCTN1 Blocking Peptide |
|||
| 3088BP-50 | Biovision | EUR 153.00 | |
 KLF4 Blocking Peptide |
|||
| 3089BP-50 | Biovision | EUR 153.00 | |
 Lin28 Blocking Peptide |
|||
| 3091BP-50 | Biovision | EUR 153.00 | |
 Hsp27 Blocking Peptide |
|||
| 3093BP-50 | Biovision | EUR 153.00 | |
 Hsp60 Blocking Peptide |
|||
| 3094RBP-50 | Biovision | EUR 153.00 | |
 Hsc70 Blocking Peptide |
|||
| 3095BP-50 | Biovision | EUR 153.00 | |
 Hsp70 Blocking Peptide |
|||
| 3097BP-50 | Biovision | EUR 153.00 | |
 SIRT7 Blocking Peptide |
|||
| 3099BP-50 | Biovision | EUR 153.00 | |
 AT2 Blocking Peptide |
|||
| 30R-AA024 | Fitzgerald | 100 ug | EUR 241.00 |
|
Description: A synthetic AT2 Blocking peptide for use as a blocking control in assays to test for specificity of AT2 antibody, catalog no. 70R-AR006 |
|||
 UCP3 Blocking Peptide |
|||
| 30R-AU006 | Fitzgerald | 100 ug | EUR 241.00 |
|
Description: A synthetic UCP3 Blocking peptide for use as a blocking control in assays to test for specificity of UCP3 antibody, catalog no. 20R-UR003 |
|||
 PKA Blocking Peptide |
|||
| 3115BP-50 | Biovision | EUR 153.00 | |
 Raf1 Blocking Peptide |
|||
| 3116BP-50 | Biovision | EUR 153.00 | |
 Wee1 Blocking Peptide |
|||
| 3120BP-50 | Biovision | EUR 153.00 | |
 Stat1 Blocking Peptide |
|||
| 3133RBP-50 | Biovision | EUR 153.00 | |
 MAK10 Blocking Peptide |
|||
| 3134BP-50 | Biovision | EUR 153.00 | |
 ACADM Blocking Peptide |
|||
| 3137BP-50 | Biovision | EUR 153.00 | |
 ACADL Blocking Peptide |
|||
| 3139BP-50 | Biovision | EUR 153.00 | |
 ACADSB Blocking Peptide |
|||
| 3150BP-50 | Biovision | EUR 153.00 | |
ACADSB Blocking Peptide |
|||
| 3157BP-50 | Biovision | EUR 153.00 | |
 Survivin Blocking Peptide |
|||
| 3160BP-50 | Biovision | EUR 153.00 | |
 TXNRD1 Blocking Peptide |
|||
| 7005BP-50 | Biovision | EUR 153.00 | |
 EDEM2 Blocking Peptide |
|||
| 6633BP-50 | Biovision | EUR 153.00 | |
 SPHKAP Blocking Peptide |
|||
| 6656BP-50 | Biovision | EUR 153.00 | |
 USP8 Blocking Peptide |
|||
| 6658BP-50 | Biovision | EUR 153.00 | |
 EHHADH Blocking Peptide |
|||
| 6678BP-50 | Biovision | EUR 153.00 | |
 ACTH Blocking Peptide |
|||
| A1051BP-50 | Biovision | EUR 153.00 | |
 Secretin Blocking Peptide |
|||
| A1054BP-50 | Biovision | EUR 153.00 | |
 C16orf73 Blocking Peptide |
|||
| 33R-1811 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C16orf73 antibody, catalog no. 70R-4561 |
|||
 ITGBL1 Blocking Peptide |
|||
| 33R-1812 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ITGBL1 antibody, catalog no. 70R-1700 |
|||
 C6ORF21 Blocking Peptide |
|||
| 33R-1813 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C6orf21 antibody, catalog no. 70R-1743 |
|||
 PNPLA3 Blocking Peptide |
|||
| 33R-1814 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PNPLA3 antibody, catalog no. 70R-2371 |
|||
 SERPINF2 Blocking Peptide |
|||
| 33R-1815 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SERPINF2 antibody, catalog no. 70R-9700 |
|||
 SLC22A16 Blocking Peptide |
|||
| 33R-1816 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SLC22A16 antibody, catalog no. 70R-1824 |
|||
 MYLIP Blocking Peptide |
|||
| 33R-1817 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYLIP antibody, catalog no. 70R-2736 |
|||
 PBEF1 Blocking Peptide |
|||
| 33R-1818 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PBEF1 antibody, catalog no. 70R-1027 |
|||
 WNT9B Blocking Peptide |
|||
| 33R-1820 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of WNT9B antibody, catalog no. 70R-7246 |
|||
 TM4SF4 Blocking Peptide |
|||
| 33R-1822 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TM4SF4 antibody, catalog no. 70R-7470 |
|||
 ZNF550 Blocking Peptide |
|||
| 33R-1823 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF550 antibody, catalog no. 20R-1242 |
|||
 SHROOM2 Blocking Peptide |
|||
| 33R-1824 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SHROOM2 antibody, catalog no. 70R-5079 |
|||
 LOC441964 Blocking Peptide |
|||
| 33R-1825 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LOC441964 antibody, catalog no. 70R-1024 |
|||
 ADRB1 Blocking Peptide |
|||
| 33R-1826 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ADRB1 antibody, catalog no. 70R-5939 |
|||
 TCP11 Blocking Peptide |
|||
| 33R-1827 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCP11 antibody, catalog no. 70R-3950 |
|||
 KIF2B Blocking Peptide |
|||
| 33R-1828 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIF2B antibody, catalog no. 70R-5498 |
|||
 RBJ Blocking Peptide |
|||
| 33R-1829 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RBJ antibody, catalog no. 70R-5875 |
|||
 MFI2 Blocking Peptide |
|||
| 33R-1830 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MFI2 antibody, catalog no. 70R-10040 |
|||
 UNC84B Blocking Peptide |
|||
| 33R-1831 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UNC84B antibody, catalog no. 70R-6991 |
|||
 CLEC4M Blocking Peptide |
|||
| 33R-1832 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CLEC4M antibody, catalog no. 70R-8545 |
|||
 LAYN Blocking Peptide |
|||
| 33R-1833 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LAYN antibody, catalog no. 70R-7484 |
|||
 FKBP5 Blocking Peptide |
|||
| 33R-1834 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FKBP5 antibody, catalog no. 70R-2377 |
|||
 GJB6 Blocking Peptide |
|||
| 33R-1835 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GJB6 antibody, catalog no. 70R-6097 |
|||
 FZD5 Blocking Peptide |
|||
| 33R-1836 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FZD5 antibody, catalog no. 70R-7475 |
|||
 ELMOD1 Blocking Peptide |
|||
| 33R-1837 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ELMOD1 antibody, catalog no. 70R-9490 |
|||
 C9ORF127 Blocking Peptide |
|||
| 33R-1838 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf127 antibody, catalog no. 70R-7095 |
|||
 KIAA0692 Blocking Peptide |
|||
| 33R-1839 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIAA0692 antibody, catalog no. 70R-3254 |
|||
 OR13C5 Blocking Peptide |
|||
| 33R-1840 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OR13C5 antibody, catalog no. 70R-7901 |
|||
 GINS2 Blocking Peptide |
|||
| 33R-1841 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GINS2 antibody, catalog no. 70R-5625 |
|||
 RGS16 Blocking Peptide |
|||
| 33R-1842 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RGS16 antibody, catalog no. 70R-1260 |
|||
 CACNB2 Blocking Peptide |
|||
| 33R-1843 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CACNB2 antibody, catalog no. 70R-5063 |
|||
 DNER Blocking Peptide |
|||
| 33R-1844 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DNER antibody, catalog no. 20R-1277 |
|||
 RFPL3 Blocking Peptide |
|||
| 33R-1845 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RFPL3 antibody, catalog no. 70R-1162 |
|||
 PENK Blocking Peptide |
|||
| 33R-1846 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PENK antibody, catalog no. 70R-6226 |
|||
 DGKQ Blocking Peptide |
|||
| 33R-1847 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DGKQ antibody, catalog no. 70R-9133 |
|||
 NUDC Blocking Peptide |
|||
| 33R-1848 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NUDC antibody, catalog no. 70R-5520 |
|||
 PABPC5 Blocking Peptide |
|||
| 33R-1849 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PABPC5 antibody, catalog no. 70R-4840 |
|||
 TRAF1 Blocking Peptide |
|||
| 33R-1850 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TRAF1 antibody, catalog no. 70R-10512 |
|||
 ZPLD1 Blocking Peptide |
|||
| 33R-1851 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZPLD1 antibody, catalog no. 70R-7542 |
|||
 SREBF1 Blocking Peptide |
|||
| 33R-1852 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SREBF1 antibody, catalog no. 70R-10526 |
|||
 ATG4A Blocking Peptide |
|||
| 33R-1853 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ATG4A antibody, catalog no. 70R-2866 |
|||
 KRT14 Blocking Peptide |
|||
| 33R-1854 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KRT14 antibody, catalog no. 20R-1352 |
|||
 POLDIP3 Blocking Peptide |
|||
| 33R-1855 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of POLDIP3 antibody, catalog no. 70R-4847 |
|||
 SRGAP1 Blocking Peptide |
|||
| 33R-1856 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SRGAP1 antibody, catalog no. 70R-9502 |
|||
 CYLC2 Blocking Peptide |
|||
| 33R-1857 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CYLC2 antibody, catalog no. 70R-2744 |
|||
 DKKL1 Blocking Peptide |
|||
| 33R-1858 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DKKL1 antibody, catalog no. 70R-7515 |
|||
 CHD1L Blocking Peptide |
|||
| 33R-1859 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CHD1L antibody, catalog no. 70R-1304 |
|||
 MYH9 Blocking Peptide |
|||
| 33R-1860 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYH9 antibody, catalog no. 70R-2739 |
|||
 PTTG2 Blocking Peptide |
|||
| 33R-1861 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PTTG2 antibody, catalog no. 70R-8929 |
|||
 NFKBIE Blocking Peptide |
|||
| 33R-1862 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NFKBIE antibody, catalog no. 70R-8262 |
|||
 TMEM9 Blocking Peptide |
|||
| 33R-1863 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TMEM9 antibody, catalog no. 70R-7412 |
|||
 CAPS Blocking Peptide |
|||
| 33R-1864 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CAPS antibody, catalog no. 70R-5864 |
|||
 RAD54B Blocking Peptide |
|||
| 33R-1865 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RAD54B antibody, catalog no. 70R-5648 |
|||
 OASL Blocking Peptide |
|||
| 33R-1866 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OASL antibody, catalog no. 70R-5891 |
|||
 DMAP1 Blocking Peptide |
|||
| 33R-1867 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DMAP1 antibody, catalog no. 20R-1081 |
|||
 IGFALS Blocking Peptide |
|||
| 33R-1869 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IGFALS antibody, catalog no. 70R-6072 |
|||
 GPX3 Blocking Peptide |
|||
| 33R-1870 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GPX3 antibody, catalog no. 70R-5305 |
|||
 THG1L Blocking Peptide |
|||
| 33R-1871 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of THG1L antibody, catalog no. 70R-3535 |
|||
 CCT5 Blocking Peptide |
|||
| 33R-1872 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CCT5 antibody, catalog no. 70R-3888 |
|||
 MBD2 Blocking Peptide |
|||
| 33R-1873 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MBD2 antibody, catalog no. 70R-1031 |
|||
KIF2B Blocking Peptide |
|||
| 33R-1874 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIF2B antibody, catalog no. 70R-5604 |
|||
 NANOS1 Blocking Peptide |
|||
| 33R-1875 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NANOS1 antibody, catalog no. 70R-4987 |
|||
 ZNF280C Blocking Peptide |
|||
| 33R-1876 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF280C antibody, catalog no. 70R-8333 |
|||
 Zfp161 Blocking Peptide |
|||
| 33R-1877 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp161 antibody, catalog no. 70R-7991 |
|||
 SSR1 Blocking Peptide |
|||
| 33R-1878 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SSR1 antibody, catalog no. 70R-7311 |
|||
 LOC153222 Blocking Peptide |
|||
| 33R-1879 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LOC153222 antibody, catalog no. 70R-7905 |
|||
 ASB12 Blocking Peptide |
|||
| 33R-1880 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ASB12 antibody, catalog no. 70R-5841 |
|||
 NID2 Blocking Peptide |
|||
| 33R-1881 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NID2 antibody, catalog no. 70R-6064 |
|||
 ABCF3 Blocking Peptide |
|||
| 33R-1883 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ABCF3 antibody, catalog no. 70R-6278 |
|||
 SLC5A7 Blocking Peptide |
|||
| 33R-1884 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SLC5A7 antibody, catalog no. 70R-7211 |
|||
 HAO2 Blocking Peptide |
|||
| 33R-1885 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HAO2 antibody, catalog no. 70R-2913 |
|||
 Katna1 Blocking Peptide |
|||
| 33R-1887 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Katna1 antibody, catalog no. 70R-9162 |
|||
 C6ORF134 Blocking Peptide |
|||
| 33R-1888 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C6orf134 antibody, catalog no. 70R-3866 |
|||
 CPSF3 Blocking Peptide |
|||
| 33R-1889 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CPSF3 antibody, catalog no. 70R-1351 |
|||
 FBXO3 Blocking Peptide |
|||
| 33R-1890 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO3 antibody, catalog no. 70R-2790 |
|||
 MPDZ Blocking Peptide |
|||
| 33R-1891 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MPDZ antibody, catalog no. 70R-2266 |
|||
 ARHGDIG Blocking Peptide |
|||
| 33R-1892 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ARHGDIG antibody, catalog no. 70R-6038 |
|||
 PDXDC1 Blocking Peptide |
|||
| 33R-1893 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PDXDC1 antibody, catalog no. 70R-4233 |
|||
 LDLRAD1 Blocking Peptide |
|||
| 33R-1894 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LDLRAD1 antibody, catalog no. 70R-6670 |
|||
 TAF7L Blocking Peptide |
|||
| 33R-1895 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TAF7L antibody, catalog no. 20R-1157 |
|||
 POLR3GL Blocking Peptide |
|||
| 33R-1896 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of POLR3GL antibody, catalog no. 70R-10078 |
|||
 LDLRAD3 Blocking Peptide |
|||
| 33R-1897 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LDLRAD3 antibody, catalog no. 70R-9224 |
|||
 ZGPAT Blocking Peptide |
|||
| 33R-1898 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZGPAT antibody, catalog no. 70R-3509 |
|||
 Mcm10 Blocking Peptide |
|||
| 33R-1899 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Mcm10 antibody, catalog no. 70R-8186 |
|||
 HSPA1L Blocking Peptide |
|||
| 33R-1900 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HSPA1L antibody, catalog no. 70R-4431 |
|||
 SNRPN Blocking Peptide |
|||
| 33R-1901 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SNRPN antibody, catalog no. 70R-8478 |
|||
 DHRSX Blocking Peptide |
|||
| 33R-1902 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DHRSX antibody, catalog no. 70R-7875 |
|||
 TTC33 Blocking Peptide |
|||
| 33R-1903 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TTC33 antibody, catalog no. 70R-3754 |
|||
 CTAGE5 Blocking Peptide |
|||
| 33R-1904 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CTAGE5 antibody, catalog no. 70R-7102 |
|||
 CPEB4 Blocking Peptide |
|||
| 33R-1905 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CPEB4 antibody, catalog no. 70R-4969 |
|||
 FSIP1 Blocking Peptide |
|||
| 33R-1906 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FSIP1 antibody, catalog no. 70R-3397 |
|||
 DDX27 Blocking Peptide |
|||
| 33R-1907 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DDX27 antibody, catalog no. 70R-1385 |
|||
 ADD3 Blocking Peptide |
|||
| 33R-1908 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ADD3 antibody, catalog no. 70R-9940 |
|||
 C22ORF30 Blocking Peptide |
|||
| 33R-1909 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C22orf30 antibody, catalog no. 70R-4259 |
|||
 CHGN Blocking Peptide |
|||
| 33R-1910 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ChGn antibody, catalog no. 70R-6125 |
|||
 EIF2S2 Blocking Peptide |
|||
| 33R-1911 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2S2 antibody, catalog no. 70R-4904 |
|||
 OAS2 Blocking Peptide |
|||
| 33R-1912 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OAS2 antibody, catalog no. 70R-5885 |
|||
 Glycoprotein Blocking Peptide |
|||
| 33R-1913 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GPNMB antibody, catalog no. 70R-7234 |
|||
 MSH5 Blocking Peptide |
|||
| 33R-1915 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MSH5 antibody, catalog no. 70R-5579 |
|||
 DDX19B Blocking Peptide |
|||
| 33R-1916 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DDX19B antibody, catalog no. 70R-1379 |
|||
 PDS5B Blocking Peptide |
|||
| 33R-1917 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PDS5B antibody, catalog no. 70R-2864 |
|||
 C1QTNF4 Blocking Peptide |
|||
| 33R-1918 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C1QTNF4 antibody, catalog no. 70R-5423 |
|||
 AKAP7 Blocking Peptide |
|||
| 33R-1919 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of AKAP7 antibody, catalog no. 70R-3082 |
|||
 NRBP1 Blocking Peptide |
|||
| 33R-1920 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NRBP1 antibody, catalog no. 70R-9295 |
|||
 INTS12 Blocking Peptide |
|||
| 33R-1921 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of INTS12 antibody, catalog no. 70R-9072 |
|||
 FXYD5 Blocking Peptide |
|||
| 33R-1922 | Fitzgerald | 100 ug | EUR 180.00 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FXYD5 antibody, catalog no. 70R-1683 |
|||